Dynein axonemal heavy chain 17 (DNAH17)
Homo sapiens — UniProt Q9UFH2
Gene: DNAH17Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Dynein axonemal heavy chain 17 (DNAH17) is a protein from Homo sapiens identified by UniProt accession Q9UFH2, 4462 residues long. MolForge cross-references it against 0 known binders and 175 disease associations.
- UniProt accession: Q9UFH2; gene symbol DNAH17.
- Organism: Homo sapiens.
- Length: 4462 amino acids.
- Top disease associations (Open Targets): spermatogenic failure 39, neurodegenerative disease and non-syndromic male infertility due to sperm motility disorder.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Dynein axonemal heavy chain 17 |
|---|---|
| UniProt accession | Q9UFH2 |
| Gene | DNAH17 |
| Organism | Homo sapiens |
| Length | 4462 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (175)
Diseases linked to this target (Open Targets).
- spermatogenic failure 39 · score 0.68
- neurodegenerative disease · score 0.50
- non-syndromic male infertility due to sperm motility disorder · score 0.37
- Short stature · score 0.34
- Male infertility with spermatogenesis disorder · score 0.27
- reticulocyte count · score 0.26
- body height · score 0.24
- diastolic blood pressure · score 0.23
- BMI-adjusted waist-hip ratio · score 0.23
- lymphocyte count · score 0.22
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9UFH2-F9 | alphafold | PREDICTED | 89.58 | — |
| AF-Q9UFH2-F8 | alphafold | PREDICTED | 88.90 | — |
| AF-Q9UFH2-F17 | alphafold | PREDICTED | 88.49 | — |
| AF-Q9UFH2-F11 | alphafold | PREDICTED | 87.76 | — |
| AF-Q9UFH2-F10 | alphafold | PREDICTED | 87.67 | — |
| AF-Q9UFH2-F7 | alphafold | PREDICTED | 86.91 | — |
| AF-Q9UFH2-F5 | alphafold | PREDICTED | 85.84 | — |
| AF-Q9UFH2-F12 | alphafold | PREDICTED | 85.75 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9UFH2.
Amino-acid sequence (4462 residues)
MTMAPDVRLE YLEEVASIVL KFKPDKWSKL IGAEENVALF TEFFEKPDVQ VLVLTLNAAG MIIPCLGFPQ SLKSKGVYFI KTKSENINKD NYRARLLYGD ISPTPVDQLI AVVEEVLSSL LNQSENMAGW PQVVSEDIVK QVHRLKNEMF VMSGKIKGKT LLPIPEHLGS LDGTLESMER IPSSLDNLLL HAIETTIIDW SHQIRDVLSK DSAQALLDGL HPLPQVEFEF WDTRLLNLKC IHEQLNRPKV NKIVEILEKA KSCYWPALQN VYTNVTEGLK EANDIVLYLK PLRILLEEME QADFTMLPTF IAKVLDTICF IWATSEYYNT PARIIVILQE FCNQIIEMTR TFLSPEEVLK GLQGEIEEVL SGISLAVNVL KELYQTYDFC CVNMKLFFKD KEPVPWEFPS SLAFSRINSF FQRIQTIEEL YKTAIEFLKL EKIELGGVRG NLLGSLVTRI YDEVFELVKV FADCKYDPLD PGDSNFDRDY ADFEIKIQDL DRRLATIFCQ GFDDCSCIKS SAKLLYMCGG LMERPLILAE VAPRYSVMLE LFDAELDNAK ILYDAQMAAS EEGNIPLIHK NMPPVAGQLK WSLELQERLE VSMKHLKHVE HPVMSGAEAK LTYQKYDEMM ELLRCHREKI YQQWVAGVDQ DCHFNLGQPL ILRDAASNLI HVNFSKALVA VLREVKYLNF QQQKEIPDSA ESLFSENETF RKFVGNLELI VGWYNEIKTI VKAVEFLLIK SELEAIDVKL LSAETTLFWN GEGVFQYIQE VREILHNLQN RMQKAKQNIE GISQAMKDWS ANPLFERKDN KKEALLDLDG RIANLNKRYA AVRDAGVKIQ AMVAENAELF RADTLSLPWK DYVIYIDDMV LDEFDQFIRK SLSFLMDNMV IDESIAPLFE IRMELDEDGL TFNPTLEVGS DRGFLALIEG LVNDIYNVAR LIPRLAKDRM NYKMDLEDNT DLIEMREEVS SLVINAMKEA EEYQDSFERY SYLWTDNLQE FMKNFLIYGC AVTAEDLDTW TDDTIPKTPP TLAQFQEQID SYEKLYEEVS KCENTKVFHG WLQCDCRPFK QALLSTIRRW GFMFKRHLSN HVTNSLADLE AFMKVARMGL TKPLKEGDYD GLVEVMGHLM KVKERQAATD NMFEPLKQTI ELLKTYGEEM PEEIHLKLQE LPEHWANTKK LAIQVKLTVA PLQANEVSIL RRKCQQFELK QHEFRERFRR EAPFSFSDPN PYKSLNKQQK SISAMEGIME ALSKSGGLFE VPVPDYKQLK ACHREVRLLK ELWDMVVVVN TSIEDWKTTK WKDINVEQMD IDCKKFAKDM RSLDKEMKTW DAFVGLDNTV KNVITSLRAV SELQNPAIRE RHWQQLMQAT QVKFKMSEET TLADLLQLNL HSYEDEVRNI VDKAVKESGM EKVLKALDST WSMMEFQHEP HPRTGTMMLK SSEVLVETLE DNQVQLQNLM MSKYLAHFLK EVTSWQQKLS TADSVISIWF EVQRTWSHLE SIFIGSEDIR TQLPGDSQRF DDINQEFKAL MEDAVKTPNV VEATSKPGLY NKLEALKKSL AICEKALAEY LETKRLAFPR FYFVSSADLL DILSNGNDPV EVSRHLSKLF DSLCKLKFRL DASDKPLKVG LGMYSKEDEY MVFDQECDLS GQVEVWLNRV LDRMCSTLRH EIPEAVVTYE EKPREQWILD YPAQVALTCT QIWWTTEVGL AFARLEEGYE NAIRDYNKKQ ISQLNVLITL LMGNLNAGDR MKIMTICTID VHARDVVAKM IVAKVESSQA FTWQAQLRHR WDEEKRHCFA NICDAQIQYS YEYLGNTPRL VITPLTDRCY ITLTQSLHLI MGGAPAGPAG TGKTETTKDL GRALGTMVYV FNCSEQMDYK SCGNIYKGLA QTGAWGCFDE FNRISVEVLS VIAVQVKCVQ DAIRAKKKAF NFLGEIIGLI PTVGIFITMN PGYAGRAELP ENLKALFRPC AMVVPDFELI CEIMLMAEGF LEARLLARKF ITLYTLCKEL LSKQDHYDWG LRAIKSVLVV AGSLKRGDPS RAEDQVLMRA LRDFNIPKIV TDDLPVFMGL IGDLFPALDV PRKRDLNFEK IIKQSIVELK LQAEDSFVLK VVQLEELLQV RHSVFIVGNA GSGKSQVLKS LNKTYQNLKR KPVAVDLDPK AVTCDELFGI INPVTREWKD GLFSTIMRDL ANITHDGPKW IILDGDIDPM WIESLNTVMD DNKVLTLASN ERIPLNRTMR LVFEISHLRT ATPATVSRAG ILYINPADLG WNPVVSSWIE RRKVQSEKAN LMILFDKYLP TCLDKLRFGF KKITPVPEIT VIQTILYLLE CLLTEKTVPP DSPRELYELY FVFTCFWAFG GAMFQDQLVD YRVEFSKWWI NEFKTIKFPS QGTIFDYYID PDTKKFLPWT DKVPSFELDP DVPLQASLVH TTETIRIRYF MDLLMEKSWP VMLVGNAGTG KSVLMGDKLE SLNTDNYLVQ AVPFNFYTTS AMLQGVLEKP LEKKSGRNYG PPGTKKLVYF IDDMNMPEVD KYGTVAPHTL IRQHMDHRHW YDRHKLTLKD IHNCQYVACM NPTSGSFTID SRLQRHFCVF AVSFPGQEAL TTIYNTILTQ HLAFRSVSMA IQRISSQLVA AALALHQKIT ATFLPTAIKF HYVFNLRDLS NIFQGLLFST AEVLKTPLDL VRLWLHETER VYGDKMVDEK DQETLHRVTM ASTKKFFDDL GDELLFAKPN IFCHFAQGIG DPKYVPVTDM APLNKLLVDV LDSYNEVNAV MNLVLFEDAV AHICRINRIL ESPRGNALLV GVGGSGKQSL SRLAAYISGL DVFQITLKKG YGIPDLKIDL AAQYIKAAVK NVPSVFLMTD SQVAEEQFLV LINDLLASGE IPGLFMEDEV ENIISSMRPQ VKSLGMNDTR ETCWKFFIEK VRRQLKVILC FSPVGSVLRV RARKFPAVVN CTAIDWFHEW PEDALVSVSA RFLEETEGIP WEVKASISFF MSYVHTTVNE MSRVYLATER RYNYTTPKTF LEQIKLYQNL LAKKRTELVA KIERLENGLM KLQSTASQVD DLKAKLAIQE AELKQKNESA DQLIQVVGIE AEKVSKEKAI ADQEEVKVEV INKNVTEKQK ACETDLAKAE PALLAAQEAL DTLNKNNLTE LKSFGSPPDA VVNVTAAVMI LTAPGGKIPK DKSWKAAKIM MGKVDTFLDS LKKFDKEHIP EACLKAFKPY QGNPTFDPEF IRSKSTAAAG LCSWCINIVR FYEVYCDVAP KRQALEEANA ELAEAQEKLS RIKNKIAELN ANLSNLTSAF EKATAEKIKC QQEADATNRV ILLANRLVGG LASENIRWAE SVENFRSQGV TLCGDVLLIS AFVSYVGYFT KKYRNELMEK FWIPYIHNLK VPIPITNGLD PLSLLTDDAD VATWNNQGLP SDRMSTENAT ILGNTERWPL IVDAQLQGIK WIKNKYRSEL KAIRLGQKSY LDVIEQAISE GDTLLIENIG ETVDPVLDPL LGRNTIKKGK YIKIGDKEVE YHPKFRLILH TKYFNPHYKP EMQAQCTLIN FLVTRDGLED QLLAAVVAKE RPDLEQLKAN LTKSQNEFKI VLKELEDSLL ARLSAASGNF LGDTALVENL ETTKHTASEI EEKVVEAKIT EVKINEAREN YRPAAERASL LYFILNDLNK INPVYQFSLK AFNVVFEKAI QRTTPANEVK QRVINLTDEI TYSVYMYTAR GLFERDKLIF LAQVTFQVLS MKKELNPVEL DFLLRFPFKA GVVSPVDFLQ HQGWGGIKAL SEMDEFKNLD SDIEGSAKRW KKLVESEAPE KEIFPKEWKN KTALQKLCMV RCLRPDRMTY AIKNFVEEKM GSKFVEGRSV EFSKSYEESS PSTSIFFILS PGVDPLKDVE ALGKKLGFTI DNGKLHNVSL GQGQEVVAEN ALDVAAEKGH WVILQNIHLV ARWLGTLDKK LEHYSTGSHE DYRVFISAEP APSPETHIIP QGILENAIKI TNEPPTGMHA NLHKALDLFT QDTLEMCTKE MEFKCMLFAL CYFHAVVAER RKFGAQGWNR SYPFNNGDLT ISINVLYNYL EANPKVPWDD LRYLFGEIMY GGHITDDWDR RLCRTYLAEY IRTEMLEGDV LLAPGFQIPP NLDYKGYHEY IDENLPPESP YLYGLHPNAE IGFLTVTSEK LFRTVLEMQP KETDSGAGTG VSREEKVKAV LDDILEKIPE TFNMAEIMAK AAEKTPYVVV AFQECERMNI LTNEMRRSLK ELNLGLKGEL TITTDVEDLS TALFYDTVPD TWVARAYPSM MGLAAWYADL LLRIRELEAW TTDFALPTTV WLAGFFNPQS FLTAIMQSMA RKNEWPLDKM CLSVEVTKKN REDMTAPPRE GSYVYGLFME GARWDTQTGV IAEARLKELT PAMPVIFIKA IPVDRMETKN IYECPVYKTR IRGPTYVWTF NLKTKEKAAK WILAAVALLL QV
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with DNAH17?
The strongest Open Targets associations for DNAH17 are spermatogenic failure 39, neurodegenerative disease, non-syndromic male infertility due to sperm motility disorder, Short stature and Male infertility with spermatogenesis disorder.
How long is the DNAH17 protein?
The Homo sapiens DNAH17 protein (UniProt Q9UFH2) is 4462 amino acids long.
Browse: Targets: D · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9UFH2 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9UFH2 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.